The results showed that sIFITM1 treatment or IFITM1 overexpression diminished EBV infection efficiency by nearly half (Fig. 1l), suggesting an antiviral role for IFITM1 in vivo. This evidence concerns the gene IFITM1 and Epstein-Barr virus infection.